| Home / College Guide / Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief |
| Posted on Tuesday, April 16 @ 00:00:04 PDT |
SAN FRANCISCO and Dr. Nageatte Ibrahim has over 11 years of oncology industry drug development experience at Merck and GSK. Dr. Nageatte Ibrahim earned her B.S. in Molecular Biology and Biochemistry from Rutgers University and M.D. from MCP-Hahnemann/Drexel College of Medicine. We are very excited to welcome Dr. Nageatte Ibrahim onboard as our Oncology CMO in Global Clinical Development, said Dr. Innovent is a rapidly growing and cutting-edge biopharmaceutical company, said About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 5 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly (NYSE: [LLY](/equities/eli-lilly-and-co)), Roche, Sanofi (NASDAQ: [SNY](/equities/sanofi)), Adimab, Incyte (NASDAQ: [INCY](/equities/incyte-corp)) and MD Anderson Cancer Center.
Guided by the motto, Start with Integrity, Succeed through Action, Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook (NASDAQ: [META](/equities/facebook-inc)) and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words anticipate, believe, estimate, expect, intend and similar expressions, as they relate to Innovent Biologics (Innovent), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Companys control and are difficult to predict.
Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Companys competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
|
|
| |
|
